新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Aegerion高胆固醇血症新药lomitapide获FDA批准

Aegerion高胆固醇血症新药lomitapide获FDA批准

来源:生物谷 2012-12-25 15:56

2012年12月25日讯 /生物谷BIOON/ --FDA已经批准Aegerion's公司治疗同合子家族性高胆固醇血症(HoFH)的新药,为这种新药的上市清除阻碍。Aegerion's公司的新药名为lomitapide。

同合子家族性高胆固醇血症(HoFH)是一种非常罕见地遗传病,患者体内的高LDL水平往往导致极其严重的心血管问题。

但是,治疗HoFH的药物一直因为可能具有较大的危险而被谨慎对待,包括对此次通过的Lomitapide,一些专家也持谨慎态度。因此,Lomitapide正式获得批准上市,或许还有很大不确定性。(生物谷Bioon.com)

详细英文报道:

The FDA has approved Aegerion's ($AEGR) new drug for homozygous familial hypercholesterolemia, clearing a path to begin commercialization as the biotech comes to a major turning point. Lomitapide will now hit the market as Juxtapid featuring a boxed warning about the distinct threat of liver toxicity.

"We are excited that Juxtapid will become a new treatment option for patients with HoFH," said Marc Beer, the CEO at Aegerion. "The approval of our first product also marks an important corporate milestone for Aegerion and reflects our commitment to help patients in need."

Homozygous familial hypercholesterolemia is an extremely rare genetic condition characterized by dangerously high levels of LDL which can trigger a lethal set of cardiovascular conditions. A significant percentage of patients in the small pivotal study Aegerion mounted demonstrated a spike in liver enzymes, a classic red flag for drug developers. A REMS program will be required to monitor patients and educate physicians.

The approval marks a big milestone for the biotech, which will handle commercialization. Aegerion has been growing a small commercial operation, bringing its total staff count to about 70. That's a big change over just a couple of years. And the biotech will keep its eyes focused on lomitapide, with no other programs competing for attention. CEO Marc Beer told FierceBiotech recently that an OK would put the company on a path to profitability in 2014, completing a turnaround he started two years ago.

Lomitapide came up for FDA review at about the same time as mipomersen, from Isis ($ISIS) and Sanofi ($SNY). But that HoFH drug faces a much more problematic future. An EMA committee recently voted against approval, raising red flags over some severe risks associated with the treatment. And only a slight majority of FDA experts gave the treatment a thumbs-up, signaling that it may face tougher odds on a formal approval.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库